Mechanisms and clinical implications of hepatocyte lipoapoptosis

Clinical Lipidology

Volumn 5, Issue 1, 2010, Pages 71-85

  Cazanave, Sophie C ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

BH3 only proteins; C Jun N terminal kinase; CCAAT enhancer binding homologous protein; Death receptor; Endoplasmic reticulum stress; Hepatic steatosis; Nonalcoholic steatohepatitis

Indexed keywords

BH3 PROTEIN; CASPASE INHIBITOR; CATHEPSIN B INHIBITOR; CERAMIDE; CHAPERONE; CHOLESTEROL; FATTY ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; OMEGA 3 FATTY ACID; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNSATURATED FATTY ACID;

CELL DEATH; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FATTY ACID DESATURATION; FATTY LIVER; HEPATOCYTE LIPOAPOPTOSIS; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIVER FATTY DEGENERATION; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 77649132053     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.09.85     Document Type: Review

References (122)

1. Angulo P, Lindor KD: Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17(Suppl.) S186-S190 (2002).
2. Adams LA, Lymp JF, St Sauver J et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129(1), 113-121 (2005).
3. Ekstedt M, Franzen LE, Mathiesen UL et al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44(4), 865-873 (2006).
4. Ratziu V, Poynard T: Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44(4), 802-805 (2006).
5. Chavez-Tapia NC, Mendez-Sanchez N, Uribe M: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 144(5), 379; author reply 380 (2006). (Pubitemid 46768200)
6. Parekh S, Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132(6), 2191-2207 (2007).
7. Lee RG: Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 21(6), 1742-1743 (1995).
8. Roden M: Mechanisms of disease: hepatic steatosis in Type 2 diabetes - pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2(6), 335-348 (2006).
9. Unger RH: Lipotoxic diseases. Annu. Rev. Med. 53, 319-336 (2002).
10. Kusminski CM, Shetty S, Orci L et al.: Diabetes and apoptosis: lipotoxicity. Apoptosis 14(12), 1484-1495 (2009).
11. Malhi H, Bronk SF, Werneburg NW et al.: Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281(17), 12093-12101 (2006).
12. Barreyro FJ, Kobayashi S, Bronk SF et al.: Transcriptional regulation of Bim by FoxO3a mediates hepatocyte lipoapoptosis. J. Biol. Chem. 282(37), 27141-27154 (2007).
13. Cazanave SC, Mott JL, Elmi NA et al.: JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J. Biol. Chem. 284(39), 26591-26602 (2009).
14. Masuoka HC, Mott J, Bronk SF et al.: Mcl-1 degradation during hepatocyte lipoapoptosis. J. Biol. Chem. 284(44), 30039-30048 (2009).
15. Wei Y, Wang D, Topczewski F et al.: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 291(2), E275-E281 (2006). (Pubitemid 44035286)
16. Wang D, Wei Y, Pagliassotti MJ: Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147(2), 943-951 (2006). (Pubitemid 43113013)
17. Wei Y, Wang D, Gentile CL et al.: Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol. Cell. Biochem. 331(1-2), 31-40 (2009).
18. Listenberger LL, Han X, Lewis SE et al.: Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl Acad. Sci. USA 100(6), 3077-3082 (2003).
19. Yamaguchi K, Yang L, McCall S et al.: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45(6), 1366-1374 (2007).
20. Larter CZ, Yeh MM, Haigh WG et al.: Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J. Hepatol. 48(4), 638-647 (2008).
21. Larter CZ, Yeh MM, Williams J et al.: MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J. Hepatol. 49(3), 407-416 (2008).
22. Feldstein AE, Canbay A, Angulo P et al.: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125(2), 437-443 (2003).
23. Nehra V, Angulo P, Buchman AL et al.: Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46(11), 2347-2352 (2001).
24. Feldstein AE, Wieckowska A, Lopez AR et al.: Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50(4), 1072-1078 (2009).
25. Lewis GF, Carpentier A, Adeli K et al.: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and Type 2 diabetes. Endocr. Rev. 23(2), 201-229 (2002).
26. Donnelly KL, Smith CI, Schwarzenberg SJ et al.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115(5), 1343-1351 (2005).
27. Pohl J, Ring A, Hermann T et al.: Role of FATP in parenchymal cell fatty acid uptake. Biochim. Biophys. Acta 1686(1-2), 1-6 (2004). (Pubitemid 39446872)
28. Zhou J, Febbraio M, Wada T et al.: Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR-g in promoting steatosis. Gastroenterology 134(2), 556-567 (2008).
29. Doege H, Baillie RA, Ortegon AM et al.: Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130(4), 1245-1258 (2006).
30. Doege H, Grimm D, Falcon A et al.: Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem. 283(32), 22186-22192 (2008).
31. Koonen DP, Jacobs RL, Febbraio M et al.: Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56(12), 2863-2871 (2007).
32. Baumgardner JN, Shankar K, Hennings L et al.: A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G27-G38 (2008).
33. Greco D, Kotronen A, Westerbacka J et al.: Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 294(5), G1281-G1287 (2008).
34. Westerbacka J, Kolak M, Kiviluoto T et al.: Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56(11), 2759-2765 (2007).
35. Mitsuyoshi H, Yasui K, Harano Y et al.: Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol. Res. 39(4), 366-373 (2009).
36. Newberry EP, Xie Y, Kennedy S et al.: Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J. Biol. Chem. 278(51), 51664-51672 (2003).
37. Newberry EP, Kennedy SM, Xie Y et al.: Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Mol. Cell. Biochem. 326(1-2), 79-86 (2009).
38. Charlton M, Viker K, Krishnan A et al.: Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49(4), 1375-1384 (2009).
39. de Almeida IT, Cortez-Pinto H, Fidalgo G et al.: Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr. 21(3), 219-223 (2002).
40. Diraison F, Moulin P, Beylot M: Contribution of hepatic de novo lipogenesis and re-esterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29(5), 478-485 (2003).
41. Puri P, Baillie RA, Wiest MM et al.: A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46(4), 1081-1090 (2007).
42. Allard JP, Aghdassi E, Mohammed S et al.: Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J. Hepatol. 48(2), 300-307 (2008).
43. Mu YM, Yanase T, Nishi Y et al.: Saturated FFAs, palmitic acid and stearic acid, induce apoptosis in human granulosa cells. Endocrinology 142(8), 3590-3597 (2001).
44. Li ZZ, Berk M, McIntyre TM et al.: Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 284(9), 5637-5644 (2009).
45. Akazawa Y, Cazanave S, Mott JL et al.: Palmitoleate attenuates palmitate-induced Bim and PUMA upregulation and hepatocyte lipoapoptosis. J. Hepatol. (2009) (In press).
46. Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8(7), 519-529 (2007).
47. Lu PD, Harding HP, Ron D: Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167(1), 27-33 (2004).
48. Luo S, Baumeister P, Yang S et al.: Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J. Biol. Chem. 278(39), 37375-37385 (2003).
49. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN et al.: XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21(1), 81-93 (2004).
50. Urano F, Wang X, Bertolotti A et al.: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287(5453), 664-666 (2000).
51. Yamamoto K, Sato T, Matsui T et al.: Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6a and XBP1. Dev. Cell 13(3), 365-376 (2007).
52. Wu J, Rutkowski DT, Dubois M et al.: ATF6a optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell 13(3), 351-364 (2007).
53. Ozcan U, Cao Q, Yilmaz E et al.: Endoplasmic reticulum stress links obesity, insulin action, and Type 2 diabetes. Science 306(5695), 457-461 (2004).
54. Puri P, Mirshahi F, Cheung O et al.: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134(2), 568-576 (2008).
55. Borradaile NM, Han X, Harp JD et al.: Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 47(12), 2726-2737 (2006).
56. Ma Y, Hendershot LM: ER chaperone functions during normal and stress conditions. J. Chem. Neuroanat. 28(1-2), 51-65 (2004).
57. Scorrano L, Oakes SA, Opferman JT et al.: BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300(5616), 135-139 (2003).
58. Cunha DA, Hekerman P, Ladriere L et al.: Initiation and execution of lipotoxic ER stress in pancreatic b-cells. J. Cell Sci. 121(Pt 14), 2308-2318 (2008).
59. Ji C, Mehrian-Shai R, Chan C et al.: Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol. Clin. Exp. Res. 29(8), 1496-1503 (2005).
60. McCullough KD, Martindale JL, Klotz LO et al.: Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 21(4), 1249-1259 (2001).
61. Puthalakath H, O'Reilly LA, Gunn P et al.: ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129(7), 1337-1349 (2007).
62. Feldstein AE, Werneburg NW, Li Z et al.: Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am. J. Physiol. Gastrointest. Liver Physiol. 290(6), G1339-G1346 (2006).
63. Yamaguchi H, Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem. 279(44), 45495-45502 (2004).
64. Guicciardi ME, Gores GJ: Life and death by death receptors. FASEB J. 23(6), 1625-1637 (2009).
65. Malhi H, Barreyro FJ, Isomoto H et al.: Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56(8), 1124-1131 (2007).
66. Volkmann X, Fischer U, Bahr MJ et al.: Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46(5), 1498-1508 (2007).
67. Ribeiro PS, Cortez-Pinto H, Sola S et al.: Hepatocyte apoptosis, expression of death receptors, and activation of NF-kB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99(9), 1708-1717 (2004).
68. Feldstein AE, Canbay A, Guicciardi ME et al.: Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39(6), 978-983 (2003).
69. Siebler J, Schuchmann M, Strand S et al.: Enhanced sensitivity to CD95-induced apoptosis in ob/ob mice. Dig. Dis. Sci. 52(9), 2396-2402 (2007).
70. Schattenberg JM, Singh R, Wang Y et al.: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43(1), 163-172 (2006).
71. Singh R, Wang Y, Xiang Y et al.: Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49(1), 87-96 (2009).
72. Wang Y, Ausman LM, Russell RM et al.: Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J. Nutr. 138(10), 1866-1871 (2008).
73. Jaeschke A, Davis RJ: Metabolic stress signaling mediated by mixed-lineage kinases. Mol. Cell 27(3), 498-508 (2007).
74. Czaja MJ: The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. Am. J. Physiol. Gastrointest. Liver Physiol. 284(6), G875-G8759 (2003).
75. Czaja MJ: Cell signaling in oxidative stress-induced liver injury. Semin. Liver Dis. 27(4), 378-389 (2007).
76. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103(2), 239-252 (2000).
77. Kodama Y, Taura K, Miura K et al.: Antiapoptotic effect of c-Jun N-terminal kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 136(4), 1423-1434 (2009).
78. Sabapathy K, Hochedlinger K, Nam SY et al.: Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15(5), 713-725 (2004).
79. Videla LA, Tapia G, Rodrigo R et al.: Liver NF-kB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 17(5), 973-979 (2009).
80. Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 19(12), 8469-8478 (1999).
81. Donovan N, Becker EB, Konishi Y et al.: JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J. Biol. Chem. 277(43), 40944-40949 (2002).
82. Lei K, Davis RJ: JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl Acad. Sci. USA 100(5), 2432-2437 (2003).
83. Kim BJ, Ryu SW, Song BJ: JNK-and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 281(30), 21256-21265 (2006).
84. Eichhorst ST, Muller M, Li-Weber M et al.: A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol. 20(20), 7826-7837 (2000).
85. Erlacher M, Labi V, Manzl C et al.: Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203(13), 2939-2951 (2006).
86. Yamaguchi H, Wang HG: Bcl-xL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL. J. Biol. Chem. 277(44), 41604-41612 (2002).
87. Adams JM, Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26(9), 1324-1337 (2007).
88. Gallenne T, Gautier F, Oliver L et al.: Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J. Cell Biol. 185(2), 279-290 (2009).
89. Chipuk JE, Fisher JC, Dillon CP et al.: Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc. Natl Acad. Sci. USA 105(51), 20327-20332 (2008).
90. Jabbour AM, Heraud JE, Daunt CP et al.: Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ. 16(4), 555-563 (2009).
91. Taylor RC, Cullen SP, Martin SJ: Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9(3), 231-241 (2008).
92. Li Z, Berk M, McIntyre TM et al.: The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47(5), 1495-1503 (2008).
93. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120(5), 1183-1192 (2001).
94. Caldwell SH, Swerdlow RH, Khan EM et al.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31(3), 430-434 (1999).
95. Caldwell SH, Chang CY, Nakamoto RK et al.: Mitochondria in nonalcoholic fatty liver disease. Clin. Liver Dis. 8(3), 595-617, (2004).
96. Summers SA: Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45(1), 42-72 (2006).
97. Holland WL, Brozinick JT, Wang LP et al.: Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5(3), 167-179 (2007).
98. Shimabukuro M, Zhou YT, Levi M et al.: Fatty acid-induced b cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA 95(5), 2498-2502 (1998).
99. Unger RH, Orci L: Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta 1585(2-3), 202-212 (2002).
100. Paumen MB, Ishida Y, Muramatsu M et al.: Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J. Biol. Chem. 272(6), 3324-3329 (1997).
101. Shah C, Yang G, Lee I et al.: Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J. Biol. Chem. 283(20), 13538-13548 (2008).
102. Kolak M, Westerbacka J, Velagapudi VR et al.: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56(8), 1960-1968 (2007).
103. Paris F, Grassme H, Cremesti A et al.: Natural ceramide reverses Fas resistance of acid sphingomyelinase-/-hepatocytes. J. Biol. Chem. 276(11), 8297-8305 (2001).
104. Kotronen A, Seppanen-Laakso T, Westerbacka J et al.: Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58(1), 203-208 (2009).
105. Mari M, Caballero F, Colell A et al.: Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab. 4(3), 185-198 (2006).
106. Ichi I, Nakahara K, Kiso K et al.: Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 23(7-8), 570-574 (2007).
107. Feng B, Yao PM, Li Y et al.: The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 5(9), 781-792 (2003).
108. Devries-Seimon T, Li Y, Yao PM et al.: Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the Type A scavenger receptor. J. Cell Biol. 171(1), 61-73 (2005).
109. Calamita G, Portincasa P: Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin. Ther. Targets. 11(9), 1231-1249 (2007). (Pubitemid 47527327)
110. Lin HZ, Yang SQ, Chuckaree C et al.: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6(9), 998-1003 (2000).
111. Nair S, Diehl AM, Wiseman M et al.: Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol. Ther. 20(1), 23-28 (2004).
112. Witek RP, Stone WC, Karaca FG et al.: Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50(5), 1421-1430 (2009).
113. Fromenty B, Robin MA, Igoudjil A et al.: The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 30(2), 121-138 (2004).
114. Feldstein AE, Werneburg NW, Canbay A et al.: Free fatty acids promote hepatic lipotoxicity by stimulating TNF-a expression via a lysosomal pathway. Hepatology 40(1), 185-194 (2004).
115. Svegliati-Baroni G, Candelaresi C, Saccomanno S et al.: A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-a and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 169(3), 846-860 (2006).
116. Araya J, Rodrigo R, Videla LA et al.: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond). 106(6), 635-643 (2004).
117. Videla LA, Rodrigo R, Araya J et al.: Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic. Biol. Med. 37(9), 1499-1507 (2004).
118. Capanni M, Calella F, Biagini MR et al.: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol. Ther. 23(8), 1143-1151 (2006).
119. Spadaro L, Magliocco O, Spampinato D et al.: Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 40(3), 194-199 (2008).
120. Ozcan U, Yilmaz E, Ozcan L et al.: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of Type 2 diabetes. Science 313(5790), 1137-1140 (2006).
121. Lindor KD, Kowdley KV, Heathcote EJ et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39(3), 770-778 (2004).
122. Cnop M, Igoillo-Esteve M, Cunha DA et al.: An update on lipotoxic endoplasmic reticulum stress in pancreatic b-cells. Biochem. Soc. Trans. 36(Pt 5), 909-915 (2008).